The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 28, 2018

Filed:

Nov. 18, 2014
Applicant:

Nanopharmaceuticals Llc, Rensselaer, NY (US);

Inventors:

Shaker A. Mousa, Wynantskill, NY (US);

Paul J. Davis, West Sand Lake, NY (US);

Assignee:

NANOPHARMACEUTICALS LLC, Rensselaer, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/78 (2006.01); G01N 33/74 (2006.01); A61K 47/32 (2006.01); A61K 31/192 (2006.01); A61K 47/10 (2017.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
G01N 33/78 (2013.01); A61K 31/192 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); G01N 33/5088 (2013.01); G01N 33/574 (2013.01); G01N 33/743 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7014 (2013.01);
Abstract

A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.


Find Patent Forward Citations

Loading…